Login
$ARQT
$27.15 -$1.11 (3.93%) Live

$ARQT SEC Filings

Filed On Filing
10 Nov 2026 SCHEDULE 13G
04 Nov 2026 Form 4: Matsuda Masaru, EVP, Chief Legal Officer

Sold 1,219 shares ($38.8K) · Received 40,000 shares by exercise or conversion ($146K) · Sold 40,000 shares ($1.37M)

04 Nov 2026 Form 3: Lisicki Robert, EVP, Chief Commercial Officer

Holds 55,000 shares of Common Stock

04 Nov 2026 Form 4: Burnett Patrick, EVP, Chief Medical Officer

Sold 943 shares ($30K)

04 Nov 2026 Form 3/A: Scott Robert A, Director

Holds 17,523 shares of Common Stock

04 Nov 2026 Form 4: Watanabe Todd, Director

Sold 4,377 shares ($139K)

04 Nov 2026 144
04 Nov 2026 424B5
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

Westlake Village, CA, November 4, 2026 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for ...

02 Nov 2026 144
02 Nov 2026 144
02 Nov 2026 144
28 Oct 2026 Form 3: Scott Robert A, Director

No securities owned

28 Oct 2026 Form 4: Scott Robert A, Director

Received 2,819 shares as a grant or award · Granted 29,170 Stock Option (right to buy)

28 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Exhibit 99.1 FOR IMMEDIATE RELEASE Arcut is Appoints Rob Scot t, MD to Board of Directors WESTLAKE VILLAGE, Calif., Oct . 28, 2026 – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on de...

20 Oct 2026 144
19 Oct 2026 Form 4: Welgus Howard G., Director

Received 4,094 shares by exercise or conversion ($32.5K) · Sold 4,728 shares ($127K)

15 Oct 2026 144
05 Oct 2026 SCHEDULE 13G/A

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support